• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Improved solubility of milk thistle extract. In the present specification there is disclosed a process for the production of a potent marian milk thistle extract. Said process involves the addition of an oil to the milk thistle extract leading to an increase in the rate of release of the vegetable drug. Also disclosed in the present specification is a product obtained by a process for the production of a potent marian milk thistle extract and the uses of said product. (Machine-translation by Google Translate, not legally binding)
    公开号:ES2706008A1
    申请号:ES201830854
    申请日:2018-08-30
    公开日:2019-03-27
    发明作者:Prous Santiago Rull；Daltell Anna Mula；Gonzalez Agustin Villar
    申请人:Euromed SA；
    IPC主号:
    专利说明:

    [0001]
    [0002] Improved solubility of milk thistle extract
    [0003]
    [0004] BACKGROUND OF THE INVENTION
    [0005]
    [0006] The efficacy of the drug silymarin, extracted from the milk thistle fruit, in the treatment and prevention of various forms of liver and gallbladder dysfunction is known. For the general preparation of a milk thistle extract, the vegetable drug (silymarin) is extracted, purified and dried, followed by a degreasing of the milk thistle fruit. It is known that flavonolignans comprising the plant drug have very little solubility in water or are not soluble. This solubility characteristic hinders the rate of release of these compounds and, thus, their bioavailability / absorption capacity in the body of humans or mammals is inadequate.
    [0007]
    [0008] CHARACTERISTICS OF THE INVENTION
    [0009]
    [0010] In the present document, an extract of milk thistle obtained through the following process is disclosed:
    [0011] (a) provide an extract of oily milk thistle obtained by defatting the milk thistle fruit
    [0012] (b) collecting the oily extract from (a) in an organic solvent to form a solution; (c) providing an additional extract from the defatted milk thistle fruit, in which the additional extract is obtained by washing the defatted milk thistle fruit with a solvent and, subsequently, removing said solvent;
    [0013] (d) collecting the additional extract from (c) in a solvent to form a solution;
    [0014] (e) combining the solution of (b), with the solution of (d) to form a combined solution of extracts, such that the amount of oily extract of (a) in the final product of (f) is 0 , 5-10.0% by weight;
    [0015] (f) removing the solvent from the combined extract solution of (e) to obtain a solid and, optionally, pulverizing the solid;
    [0016] wherein the product has a silymarin release rate of 90% or higher.
    [0017]
    [0018] In one embodiment, the solution of (b) is concentrated and / or filtered. In one embodiment, the solution of (d) is concentrated and / or filtered. In one embodiment, the solution of (e) is concentrated and / or filtered. In one embodiment, the dry extract of (c) and / or (f) is sprayed. In one embodiment, the dry extract of (c) is re solvated in an organic solvent, optionally, concentrated and / or optionally filtered and dried and, optionally, sprayed before step (d). In one embodiment, the oily marian milk thistle extract from (a) is obtained by cold pressing of the milk thistle fruit. In one embodiment, the oily marian milk thistle extract from (a) is obtained by washing the milk thistle fruit with an organic solvent. In one embodiment, the solvent is a hydrocarbon solvent. In one embodiment, the oily milk thistle extract of (a) is obtained by extraction with gases or supercritical fluids. In one embodiment, the extraction is carried out with supercritical carbon dioxide. In one embodiment, the oily milk thistle extract obtained from (a) is 5-35% by weight of the unprocessed milk thistle fruit, in which the remaining 65-95% is the fruit of the defatted milk thistle. In one embodiment, the solvent of (b) is an alcohol. In one embodiment, the solvent is ethanol. In one embodiment, the solvent of (c) is ethyl acetate, ethanol, methanol or acetone. In one embodiment, the solvent of (c) is ethyl acetate. In one embodiment, the solvent of claim (d) is an alcohol. In one embodiment, the solvent is ethanol. In one embodiment, the amount of oily extract in (e) is 0.5-6.0% by weight. In one embodiment, the amount of oily extract in (e) is 1-3% by weight. In one embodiment, the product has a silymarin release rate of 91% or higher.
    [0019]
    [0020] In the present specification there is disclosed a milk thistle product comprising an extract of milk thistle and an oil. In one embodiment, the milk thistle extract is obtained by washing a defatted milk thistle fruit with a solvent and then removing said solvent afterwards. In one embodiment, the defatted milk thistle fruit is obtained by cold pressing, thus extracting a milk thistle oil. In one embodiment, the oil is a vegetable oil, an animal oil, a petroleum oil, or any combination thereof. In one embodiment, the oil is a vegetable oil, an essential oil, an herbal oil, or any combination thereof. In one embodiment, the oil is a milk thistle oil. In one embodiment, the milk thistle oil is obtained by defatting the milk thistle fruit. In one embodiment, the degreasing process is cold pressing. In one embodiment, the milk thistle extract is obtained by washing the defatted milk thistle fruit with ethyl acetate, ethanol, or methanol, and then removing said solvent afterwards. In one embodiment, the product is obtained by the combination of milk thistle oil with solvated milk thistle extract, and the elimination of all solvents.
    [0021] In the present specification there is provided a pharmaceutical composition comprising a therapeutically effective amount of a product of any of the processes disclosed in the present specification. In one embodiment, the pharmaceutical composition comprises, at a minimum, a pharmaceutically acceptable carrier. In one embodiment, the pharmaceutical composition is a pill, lozenge, capsule, pill, granule, suppository, solution, syrup, suspension, or emulsion.
    [0022]
    [0023] In the present specification there is disclosed a method for the treatment or prevention of diseases of the liver, stomach or gall bladder in a subject by the administration of any of the products disclosed herein. In one embodiment, liver disease is hepatic damage by toxicity, hepatosis, acute liver failure, hepatic necrosis, hepatic dystrophy, liver cirrhosis, hepatic fibrosis, hepatomegaly, fatty degeneration of the liver, liver failure and hepatitis. In one embodiment, the liver disease is selected from the group comprising fascioliasis, hepatitis, non-alcoholic steatohepatitis (NASH) with fibrosis or without fibrosis, hepatic steatosis, fatty liver disease (FLD), non-alcoholic fatty liver disease (NAFLD). , alcoholic liver disease, Allagille syndrome, biliary atresia, galactosemia, gallstones, hemochromatosis, liver cancer, deficiency of lysosomal acid lipase (LALD), porphyria, acetaminophen hepatotoxicity, Reye's syndrome, sarcoidosis, tyrosinemia, Wilson's disease , Gilbert's syndrome, cirrhosis and primary sclerosing cholangitis. In one embodiment, hepatitis is hepatitis C. In one embodiment, the liver disease is non-alcoholic fatty liver disease.
    [0024]
    [0025] In the present specification there is disclosed a process for the preparation of extract of the milk thistle fruit having a release rate of silymarin of 90% or higher, the method comprising:
    [0026] (a) provide an oily milk thistle extract obtained by defatting the milk thistle fruit;
    [0027] (b) collecting the oily extract from (a) in an organic solvent to form a solution; (c) providing an additional extract of defatted milk thistle fruit, in which the additional extract is obtained by washing the defatted milk thistle fruit with a solvent and then removing said solvent;
    [0028] (d) collecting the additional extract from (c) in a solvent to form a solution;
    [0029] (e) combining the solution of (b), with the solution of (d) to form a combined solution of extracts, such that the amount of oily extract of (a) in the final product of (f) it is 0.5-10.0% by weight;
    [0030] (f) removing the solvent from the combined extract solution of (e) to obtain a solid and, optionally, pulverize the solid.
    [0031]
    [0032] In one embodiment, the solution of (b) is concentrated and / or filtered. In one embodiment, the solution of (d) is concentrated and / or filtered. In one embodiment, the solution of (e) is concentrated and / or filtered. In one embodiment, the dry extract of (c) and / or (f) is sprayed. In one embodiment, the dry extract of (c) is re solvated in an organic solvent, optionally, concentrated and / or optionally filtered and dried and, optionally, sprayed before step (d). In one embodiment, the oily milk thistle extract of (a) is obtained by cold pressing the milk thistle fruit. In one embodiment, the oily marian milk thistle extract from (a) is obtained by washing the milk thistle fruit with an organic solvent. In one embodiment, the solvent is a hydrocarbon solvent. In one embodiment, the oily marian milk thistle extract from (a) is obtained by extraction with gases or supercritical fluids or in combination therewith. In one embodiment, the extraction is carried out with supercritical carbon dioxide. In one embodiment, the oily milk thistle extract obtained from (a) is 5-35% by weight of the unprocessed milk thistle fruit, in which 65-95% of the remaining weight is the fruit of the defatted milk thistle. In one embodiment, the solvent of (b) is an alcohol. In one embodiment, the solvent is ethanol. In one embodiment, the solvent of (c) is ethyl acetate, ethanol or methanol. In one embodiment, the solvent of (c) is ethyl acetate. In one embodiment, the solvent of claim (d) is an alcohol. In one embodiment, the solvent is ethanol. In one embodiment, the amount of oily extract in (e) is 0.5-6.0% by weight. The process according to claim 58, wherein the amount of oily extract in (e) is 1-3% by weight.
    [0033]
    [0034] A product of any of the processes disclosed herein is disclosed in the present specification, wherein the product has a silymarin release rate of 91% or higher.
    [0035]
    [0036] In the present specification there is disclosed a process for the preparation of an enhanced marinated milk thistle extract comprising an extract of milk thistle and an oil, wherein the addition of said oil to said milk thistle extract results in a increase in the release rate of silymarin.
    [0037]
    [0038] In one embodiment, the oil is derived from vegetable, animal or petrochemical sources. In One embodiment, the oil is derived from a plant. In one embodiment, the oil is derived from fruits, seeds or vegetables. In one embodiment, the oil is derived from fruits and / or seeds of milk thistle. In one embodiment, the release rate is improved by 1.0% or more. In one embodiment, the release rate is improved by 5.0% or more. In one embodiment, the release rate is improved by 10.0% or more. In one embodiment, the release rate is improved by 20.0% or more.
    [0039]
    [0040] DETAILED DESCRIPTION OF THE INVENTION
    [0041]
    [0042] In one embodiment, the present invention relates to a process for the preparation of an extract of the milk thistle fruit, in particular, a flavonolignan preparation, which has an increased release rate, and to the use thereof, in particular, for the treatment and prevention of liver diseases. The present specification also discloses a product that is made by the process thereof, since the milk thistle extract disclosed in the present specification contains a mixture of chemical compounds of natural origin, many of which they are isomeric
    [0043]
    [0044] In one embodiment, the present specification discloses a process for the production of an extract of the milk thistle fruit with an increased release rate of silymarin. In some cases, the extract is prepared essentially without additives, supplements, carrier substances, or wetting agents. In an embodiment of the present invention described herein, a method for the preparation of a milk thistle extract having a release rate of silymarin of 90% or higher, using only components of the thistle fruit, is given. Mariano
    [0045]
    [0046] In general, the preparation of an extract of the milk thistle fruit requires, in the first place, the elimination of an oily fraction within the milk thistle fruit. In some preparations, this oily fraction is rejected or used as an oil in an unrelated product, while the defatted milk thistle plant is washed with organic solvents to extract the drug from silymarin. Next, the washes are processed to produce a solid extract.
    [0047]
    [0048] In the present invention, which is disclosed herein, the oily fraction derived from the defatting of the milk thistle fruit is added again during the process of processing the solid extract. Unexpectedly, the addition of 0.5-10% by weight of the oily fraction to the extract produces a product with markedly superior dissolution characteristics. The addition of an oil to an extract whose main components have low solubility is not expected to increase said solubility. The addition of an oil to another substance often confers hydrophobic properties to the substance. It could also be expected that the addition of the oil would adversely affect the physical properties of the extract by increasing the adhesion capacity or decreasing the fluidity of the extracted powder. However, none of these observations have been made and the solid extract has excellent formulation properties.
    [0049]
    [0050] In an embodiment of the present invention, an oil may be added before, during or after the processing of the milk thistle extract to increase the release rate of silymarin from the extract. In some embodiments, the oily fraction is provided by defatting the milk thistle fruit itself. In further embodiments, the oil is provided from a source unrelated to the milk thistle fruit, such as a vegetable oil, an animal oil, a petroleum oil, or any combination thereof. In some cases, the vegetable oil is a vegetable oil, an essential oil, an herbal supplement oil, or any combination thereof.
    [0051]
    [0052] Terms and definitions
    [0053]
    [0054] The term "solution" refers to homogeneous and / or heterogeneous mixtures of a material and a solvent.
    [0055]
    [0056] The term "hydrocarbon solvent" refers to solvents that are constructed from hydrogen and carbon atoms Examples of solvents include, but are not limited to, any solvent or solvent mixture comprising C5-C11 alkanes. linear, branched or cyclic, such as pentane, hexane, heptane, octane, nonane, decane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, or aryl or C6-C10 arylalkanes, such as benzene, toluene, xylene or ethylbenzene. it may be applicable to solvents containing heteroatoms, such as oxygen, nitrogen and fluorine which are not perceptibly polar, examples include, but are not limited to, diethyl ether, 1,4-dichlorobenzene and methyl t-butyl ether.
    [0057]
    [0058] The term "gas or supercritical liquid" refers to a substance that is at a temperature or pressure above its critical point, in which there are no liquid or gas phases different As such, the term "supercritical gas or liquid" is equivalent to "supercritical liquid" and "supercritical gas." In addition, the terms "supercritical liquid" and "supercritical gas" are used interchangeably and are meant to refer to the same physical state of the matter Examples of substances which may be used as supercritical gases or liquids include carbon dioxide, water, methane, ethane, butane, propane, ethylene, propene, butene, ethanol, methanol, propanol, nitrous oxide and dinitrogen.
    [0059]
    [0060] The term "alcohol" preferably includes C1-C4 alcohols, particularly preferably ethanol, such as 99% pure or even 99.5%.
    [0061]
    [0062] Within the scope of the present specification, "silymarin" refers to a mixture of substances comprising (at a minimum) the four substances silibinin, silidianin, silicristin, and isosilibinin in different concentrations.
    [0063]
    [0064] A "silymarin release rate of 90% or higher" means that the active substances are, at least, soluble in aqueous solution at 90%.
    [0065]
    [0066] The term "oil" describes a greasy substance, fuel that is liquid, or easily liquifiable, after heating, and is soluble in ether but insoluble in water.The oils can be described as animal, vegetable or petrochemical, depending on their origin The term also includes long chain fatty acids, esters, alcohols, or alkanes The term also includes silicones, hydrocarbons, glycosides, glutamates, glycerides, glyceryl esters and waxes.
    [0067]
    [0068] The term "dietary supplement" refers to a product that supplements the diet.A dietary supplement is different from a drug that should undergo extensive trials and be approved in advance by the FDA before being marketed.In some cases, dietary supplements can be labeled as that have an impact on a disease or condition Dietary supplements are not represented for use as conventional food or as the only element of a meal or diet Dietary supplements are usually adapted to supplement, ie to be added to the consumption food of an individual of one or more dietary components.
    [0069]
    [0070] The term "potent marian milk thistle extract" describes a milk thistle extract obtained by a process in which an oil has been added and also has an increased rate of release or dissolution rate, when compared to a thistle extract Mariano obtained by a process that does not comprise the step of adding an oil.
    [0071]
    [0072] The terms "effective amount" or "therapeutically effective amount," as used herein, refer to a sufficient amount of an agent or a compound being administered that will relieve to some extent one or more of the symptoms of the disease or condition that is being treated. The result can be the reduction and / or relief of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, an "effective amount" for therapeutic uses is the amount of the composition comprising a compound, as disclosed in the present specification, required to provide a significant decrease in the symptoms of the disease. Adequate amount "effective" in any individual case can be determined by using techniques, such as a dose escalation study.
    [0073]
    [0074] The term "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances in which said event or circumstance occurs and cases in which it does not occur.
    [0075]
    [0076] The term "subject" or "patient" includes mammals. Examples of mammals include, but are not limited to, humans. In one embodiment, the mammal is a human.
    [0077]
    [0078] The terms "treat," "treating" or "treatment", as used herein, include alleviating, remitting or ameliorating, at a minimum, a symptom of a disease or condition, avoiding additional symptoms, inhibiting the disease or condition, for example, stopping the development of the disease or condition, alleviating the disease or condition, causing the regression of the disease or condition, alleviating a condition caused by the disease or condition, or stopping the symptoms of the disease or condition so prophylactic and / or therapeutic.
    [0079]
    [0080] The term "pharmaceutically acceptable carrier", "pharmaceutically acceptable excipient", "physiologically acceptable carrier" or "physiologically acceptable excipient" refers to a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, a diluent, a solvent or an encapsulation material. In one embodiment, each component is "pharmaceutically acceptable" in the sense of being compatible with other ingredients of the pharmaceutical formulation and suitable for use in contact with the tissue or organ of humans and animals without toxicity, irritation, allergic response, excessive immunogenicity, or other problems or complications, which corresponds to a reasonable benefit / risk ratio. See, Remington: The Science and Practice of Pharmacy ("The Science and Practice of Pharmacy"), 21st edition, Lippincott Williams & Wilkins: Philadelphia, PA, 2005; Handbook of Pharmaceutical Excipients "(Handbook of Pharmaceutical Excipients), 5a ed., Rowe et al., eds., The Pharmaceutical Press and the American Pharmaceutical Association: 2005; and Pharmaceutical additives Handbook ("Handbook of Pharmaceutical Additives"), 3rd edition, Ash and Ash eds., Gower Publishing Company: 2007; Preformulation and pharmaceutical formulation ("Pharmaceutical Preformulation and Formulation"), 2nd edition, Gibson Ed., CRC Press LLC: Boca Raton, FL, 2009.
    [0081]
    [0082] The term "approximately" or "roughly" means an acceptable error for a particular value, as determined by one skilled in the art, which depends, in part, on how the value is measured or determined. finished
    [0083] "Roughly" or "roughly" means 1, 2, 3 or 4 standard deviations. In some embodiments, the term "approximately" or "roughly" means 50%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5% or 0.05% of a given value or range.
    [0084]
    [0085] Procedure of preparation and product by process
    [0086]
    [0087] In the present description, methods for the preparation of an extract of the milk thistle fruit which include:
    [0088] (a) provide an oily milk thistle extract obtained by defatting the milk thistle fruit;
    [0089] (b) collecting the oily extract from (a) in an organic solvent to form a solution; (c) providing an additional extract of defatted milk thistle fruit, in which the additional extract is obtained by washing the defatted milk thistle fruit with a solvent and then removing said solvent;
    [0090] (d) collecting the additional extract from (c) in a solvent to form a solution;
    [0091] (e) combining a part of the solution of (b), with the solution of (d) to form a combined solution of extracts, such that the amount of oily extract of (a) in the final product of (f) it is 0.5-10.0% by weight;
    [0092] (f) removing the solvent from the combined extract solution of (e) to obtain a solid and, optionally, pulverizing the solid, wherein the product has a release rate of Silymarin 90% or higher.
    [0093]
    [0094] In one embodiment of the present specification there is disclosed a process for the preparation of milk thistle extract, wherein the addition of an oil to a milk thistle extract results in an increase in the release rate of silymarin. In some embodiments, the addition of an oil to the milk thistle extract produces an increase of 1% or more in the release rate of silymarin. In some embodiments, the addition of an oil to the milk thistle extract produces an increase of 2% or more in the release rate of silymarin. In some embodiments, the addition of an oil to the milk thistle extract produces an increase of 5% or more in the release rate of silymarin. In some embodiments, the addition of an oil to the milk thistle extract produces an increase of 10% or more in the release rate of silymarin. In some embodiments, the addition of an oil to the milk thistle extract produces an increase of 15% or more in the release rate of silymarin. In some embodiments, the addition of an oil to the milk thistle extract produces an increase of 20% or more in the release rate of silymarin. In some embodiments, the addition of an oil to the milk thistle extract produces an increase of 30% or more in the release rate of silymarin. In some embodiments, the addition of an oil to the milk thistle extract produces an increase of 50% or more in the release rate of silymarin.
    [0095]
    [0096] In another embodiment of the present specification there is disclosed a product that shows an increased release rate of silymarin. In some embodiments, the product is produced from a process comprising the step of adding an oil. The product is compared to the product obtained by a process that does not comprise the step of adding an oil. In some embodiments, the addition of an oil to the milk thistle extract produces an increase of 1% or more in the release rate of silymarin. In some embodiments, the addition of an oil to the milk thistle extract produces an increase of 2% or more in the release rate of silymarin. In some embodiments, the addition of an oil to the milk thistle extract produces an increase of 5% or more in the release rate of silymarin. In some embodiments, the addition of an oil to the milk thistle extract produces an increase of 10% or more in the release rate of silymarin. In some embodiments, the addition of an oil to the milk thistle extract produces an increase of 15% or more in the release rate of silymarin. In some embodiments, the addition of an oil to the milk thistle extract produces an increase of 20% or more in the release rate of silymarin. In some embodiments, the addition of an oil to the milk thistle extract produces an increase of 30% or more in the release rate of silymarin. In some embodiments, the addition of an oil to the milk thistle extract produces an increase of 50% or more in the release rate of silymarin.
    [0097]
    [0098] In addition, a powerful marian thistle extract produced by the following process is disclosed in the present specification:
    [0099] (a) provide an oily milk thistle extract obtained by defatting the milk thistle fruit;
    [0100] (b) collecting the oily extract from (a) in an organic solvent to form a solution; (c) providing an additional extract of defatted milk thistle fruit, in which the additional extract is obtained by washing the defatted milk thistle fruit with a solvent and then removing said solvent;
    [0101] (d) collecting the additional extract from (c) in a solvent to form a solution;
    [0102] (e) combining the solution of (b), with the solution of (d) to form a combined solution of extracts, such that the amount of oily extract of (a) in the final product of (f) is 0 , 5-10.0% by weight; (f) removing the solvent from the combined extract solution of (e) to obtain a solid and optionally pulverizing the solid, wherein the product has a silymarin release rate of 90% or higher.
    [0103]
    [0104] In some embodiments, the solution of (b) is concentrated and / or filtered. In some embodiments, the solution of (d) is concentrated and / or filtered. In some embodiments, the solution of (e) is concentrated and / or filtered. In some embodiments, the dry extract of (c) and / or (f) is sprayed. In some embodiments, the dry extract of (c) is re solvated in an organic solvent, optionally concentrated and / or optionally filtered, and dried to provide a solid, which is optionally sprayed before the step (d) ).
    [0105]
    [0106] In some embodiments, the oily marian milk thistle extract from (a) is obtained by cold pressing of the milk thistle fruit. In some embodiments, the oily marian milk thistle extract from (a) is obtained by washing the milk thistle fruit with an organic solvent.
    [0107]
    [0108] In some embodiments, the solvent of (a) is a hydrocarbon solvent. In some embodiments, the oily marian milk thistle extract from (a) is obtained by extraction with or in combination with gases or supercritical fluids. In some embodiments, the extraction is carried out with supercritical carbon dioxide. In some embodiments, the solvent of (b) is an alcohol. In some embodiments, the solvent of (b) it is ethanol. In some embodiments, the solvent of (c) is ethyl acetate, ethanol, methanol or acetone. In some embodiments, the solvent of (c) is ethyl acetate. In some embodiments, the solvent of claim (d) is an alcohol. In some embodiments, the solvent is ethanol.
    [0109]
    [0110] In some embodiments, the amount of oily extract in (e) is 0.5-6.0% by weight. In some embodiments, the amount of oily extract in (e) is 1-3% by weight.
    [0111]
    [0112] In another embodiment, the process for the preparation of an extract of the milk thistle fruit is described in a process comprising:
    [0113] (a) The fruit of the plant is degreased by mechanical cold pressing or by washing with hydrocarbon solvents or supercritical fluids. In the case where hydrocarbon solvents are used, the solvent is subsequently removed. In some cases, the oily fraction is filtered or concentrated. The isolated oily fraction is usually found in 5-35% by weight of the unprocessed milk thistle fruit. The defatted Marian thistle fruit contains the remaining weight.
    [0114] (b) The oily fraction of (a) is combined with an organic solvent to form a solution, among the non-limiting examples of which are included ethanol, propanol, diethyl ether, hexane and ethyl acetate. This solution, optionally, is concentrated and / or filtered. (c) The defatted milk thistle fruit is washed with an organic solvent, among the non-limiting examples of which are included ethyl acetate, ethanol, acetone and methanol. The resulting solution, optionally, contains aqueous fractions. The solution, optionally, is washed with hexane or other non-polar solvent. The solution is also, optionally, concentrated and / or filtered. The solution is dried, optionally, under vacuum with stirring. The resulting crude extract, optionally, is washed with hot water and dried and / or optionally sprayed.
    [0115] (d) The crude extract obtained in (c) is redissolved in an organic solvent, among the non-limiting examples of which alcohols are included, such as methanol, ethanol, propanol and butanol. The resulting solution, optionally, is concentrated and / or filtered.
    [0116] (e) The solution of (d) is combined with the solution of (b), in a proportion, such that the final product of step (f) contains 0.5-10.0% by weight of the oily fraction obtained in (a). The solution is optionally concentrated and / or filtered.
    [0117] (f) Removing the solvent from the combined extract solution of (e) to obtain a solid and, optionally, pulverizing the solid, wherein the product has a silymarin release rate of 90% or higher.
    [0118] In another embodiment, a potent marian milk thistle extract is produced by the process comprising:
    [0119] (a) The fruit of the plant is degreased by mechanical cold pressing or by washing with hydrocarbon solvents or supercritical fluids. In the case where hydrocarbon solvents are used, the solvent is subsequently removed. In some cases, the oily fraction is filtered or concentrated. The isolated oily fraction is usually found in 5-35% by weight of the unprocessed milk thistle fruit. The defatted Marian thistle fruit contains the remaining weight.
    [0120] (b) The oily fraction of (a) is combined with an organic solvent to form a solution, non-limiting examples of which include ethanol, propanol, diethyl ether, hexane and ethyl acetate. This solution, optionally, is concentrated and / or filtered.
    [0121] (c) The defatted milk thistle fruit is washed with an organic solvent, among the non-limiting examples of which are included ethyl acetate, ethanol, acetone and methanol. The resulting solution, optionally, contains aqueous fractions. The solution, optionally, is washed with hexane or other non-polar solvent. The solution is also, optionally, concentrated and / or filtered. The solution is dried, optionally, under vacuum with stirring. The resulting crude extract, optionally, is washed with hot water and dried and / or optionally, sprayed.
    [0122] (d) The crude extract obtained in (c) is redissolved in an organic solvent, among the non-limiting examples of which alcohols are included, such as methanol, ethanol, propanol and butanol. The resulting solution, optionally, is concentrated and / or filtered.
    [0123] (e) The solution of (d) is combined with the solution of (b), in a proportion such that the final product of step (f) contains 0.5-10.0% by weight of the fraction oily obtained in (a). The solution is optionally concentrated and / or filtered.
    [0124] (f) removing the solvent from the combined extract solution of (e) to obtain a solid and, optionally, pulverizing the solid, wherein the product has a silymarin release rate of 90% or higher.
    [0125]
    [0126] In some embodiments, the extraction of step (c) is carried out at 40-80 degrees Celsius. In another embodiment, the extraction is carried out at 50-70 degrees Celsius.
    [0127]
    [0128] In some embodiments, the solution of step (c) is dried at a temperature below 60 degrees Celsius. In another embodiment, the solution is dried at a temperature below 40 degrees Celsius.
    [0129]
    [0130] In some embodiments, the ethanol used in step (d) is 96% ethanol or higher. In some embodiments, the combined solutions are concentrated at a pressure of 1-100 mbar.
    [0131]
    [0132] In one embodiment, the process for the preparation of an extract of the milk thistle fruit is described in a process comprising:
    [0133] (a) provide an oily milk thistle obtained by cold pressing of the milk thistle fruit;
    [0134] (b) collecting the oily extract from (a) in ethanol to form a solution;
    [0135] (c) providing an additional extract of the defatted milk thistle fruit, in which the additional extract is obtained by washing the defatted marian milk thistle fruit with ethyl acetate and, subsequently, removing said solvent;
    [0136] (d) collecting the additional extract from (c) in ethanol to form a solution;
    [0137] (e) combining the solution of (b), with the solution of (d) to form a combined solution of extracts, such that the amount of oily extract of (a) in the final product of (f) is 1 , 0-3.0% by weight; (f) removing the solvent from the combined extract solution of (e) to obtain a solid and, optionally, pulverizing the solid, wherein the product has a silymarin release rate of 90% or higher.
    [0138]
    [0139] In one embodiment, a potent marian milk thistle extract is produced by the following process comprising:
    [0140] (a) provide an oily milk thistle obtained by cold pressing the fruit of the milk thistle;
    [0141] (b) collecting the oily extract from (a) in an ethanol to form a solution;
    [0142] (c) providing an additional extract of the defatted milk thistle fruit, in which the additional extract is obtained by washing the defatted marian milk thistle fruit with ethyl acetate and, subsequently, removing said solvent;
    [0143] (d) collecting the additional extract from (c) in an ethanol to form a solution;
    [0144] (e) combining the solution of (b), with the solution of (d) to form a combined solution of extracts, such that the amount of oily extract of (a) in the final product of (f) is 1 , 0-3.0% by weight; (f) removing the solvent from the combined extract solution of (e) to obtain a solid and, optionally, pulverizing the solid, wherein the product has a silymarin release rate of 90% or higher.
    [0145]
    [0146] In some embodiments of the present disclosure, the release rate of silymarin from the milk thistle extract is 85% or higher. In some embodiments, the release rate of silymarin is 90% or greater. In some embodiments, the rate of Silymarin release is 91% or higher.
    [0147]
    [0148] In some embodiments, a supercritical gas and / or fluid is used to degrease the milk thistle fruit in step (a). In some cases, the milk thistle fruit is cut, ground, minced or, otherwise, pulverized into a paste. The paste can be stirred or stirred in the presence of the supercritical fluid to facilitate defatting. In some embodiments, carbon dioxide is the supercritical gas in the degreasing process. In other embodiments, non-limiting examples of supercritical gases or fluids include methane, ethane, butane, propane, ethylene, propene, butene, ethanol, methanol, propanol, water, nitrous oxide and dinitrogen.
    [0149]
    [0150] In some embodiments, hydrocarbon solvents are used to degrease the milk thistle fruit. In some cases, the milk thistle fruit is cut, ground, minced or, otherwise, pulverized into a paste. The paste can be stirred or stirred in the presence of the hydrocarbon solvent to facilitate defatting. The hydrocarbon solvents include linear, branched or cyclic C5-C11 alkanes such as pentane, hexane, heptane, octane, nonane, decane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, or aryl or C6-C10 arylalkanes such as benzene, toluene, xylene or ethyl benzene. In some embodiments, said hydrocarbon solvents contain heteroatoms, such as oxygen, nitrogen and fluorine in which the molecule is not perceptibly polar, or has a dipole moment below 2. In some embodiments, the dipole moment is below of 1.5. Examples include, but are not limited to, diethyl ether, 1,4-dichlorobenzene, and methyl t-butyl ether.
    [0151]
    [0152] In some embodiments, the extraction of the oily fraction is obtained by means of cold pressing. In some embodiments, the cold pressing process involves cutting, grinding, chopping or pulverizing the raw milk thistle fruit. This results in the formation of a semi-solid paste. Next, the material is mechanically pressed to force the oily fraction out of the solid material. In some embodiments, the fraction passes through one or more filters. In some embodiments, no external heat is applied to the process during grinding, pressing or filtering.
    [0153]
    [0154] In some embodiments, the oily fraction obtained by the cold pressing of the milk thistle fruit is added back to the extract obtained by washing the defatted milk thistle fruit. The readmission of the milk thistle oil to the extract increases the release rate of silymarin in the final product. In alternative embodiments, add a different vegetable oil to the milk thistle oil to increase the release rate of silymarin. In the present specification, non-limiting examples of oils derived from plants are disclosed for use as additives, such as coconut oil, corn oil, cottonseed oil, olive oil, palm oil, peanut oil, oil. rapeseed, canola oil, safflower oil, sesame oil, soybean oil, sunflower oil, almond oil, beetroot oil, Brazil nut oil, cashew oil, hazelnut oil, macadamia oil, oil Mongolian nut, pecan oil, pine nut oil, pistachio oil, walnut oil, grapefruit seed oil, lemon oil, orange oil, bitter gourd oil, buffalo gourd oil, butternut squash seed oil , pumpkin seed oil, watermelon seed oil, acai oil, black seed oil, black currant seed oil, borage seed oil, flax seed oil, amaranth oil, apricot oil, ac eite of apple seed, argan oil, avocado oil, babassu oil, ben oil, borneo tallow nut oil, carob pod oil (carob oil), cocoa butter, sometimes known as oil Theobroma, cocklebur oil, sunflower oil, corozo oil ("cohune"), coriander seed oil, date seed oil, dika oil, fake flax oil, grape seed oil, hemp oil , kapok seed oil, kenaf seed oil, cottonseed oil, lallemantia oil, mafura oil, marula oil, prairie grass seed oil, mustard oil, niger seed oil, nutmeg oil, okra seed oil, goat seed oil, persimmon seed oil, pequi oil, pili nut oil, pomegranate seed oil, poppy seed oil, pracaxi oil, plum oil kernel, quinoa oil, ramtil oil, bran oil of rice, royle oil, sacha inchi oil, zapote oil, seje oil, shea oil, taramira oil, tea seed oil, tiger nut oil (or hazelnut oil), tobacco seed oil , tomato seed oil, wheat germ oil, agar oil, ajwain oil, angelica root oil, anise oil, asafetida oil, basil oil, bay oil, bergamot oil, pepper oil black, buchu oil, birch oil, camphor oil, hemp flower essential oil, calamydine oil, calamansi essential oil, alcarabea oil, cardamom seed oil, carrot seed oil, cedar oil ( or cedarwood oil), chamomile oil, calamus oil, cinnamon oil, lemon oil, citronella oil, clear sage oil, coconut oil, coffee oil, coriander oil, costmary oil (oil of "bible leaf"), cost root oil, oil cranberry seed, cubeba oil, cumin oil, cypress oil, cypriol oil, curry leaf oil, davana oil, elecampane oil, elemi oil, eucalyptus oil, oil fennel seed, fenugreek oil, fir oil, frankincense oil, galangal oil, galbanum oil, geranium oil, ginger oil, goldenrod oil, helichrysum oil, walnut oil, horseradish oil, jasmine oil, juniper berries oil, lavender oil, melaleuca tea tree oil, lemon balm oil, peppermint oil, moringa oil, sagebrush oil, myrrh oil, bayberry oil or Neem tree oil, oregano oil, orris oil, parsley oil, patchouli oil, goji essential oil, pennyroyal oil, peppermint oil, pine oil, rose oil, rosehip oil, rosemary oil , rosewood oil, sage oil, saffron oil, thyme oil, wild palm oil, schisandra oil, peppermint oil, spruce oil, star anise oil, tarragon oil, tea tree oil, oil of thyme, vetiver oil (oil of khus) and yarrow oil.
    [0155]
    [0156] In some embodiments, examples of animal derived oils for use in the disclosed process include, but are not limited to, bone oil, cod liver oil, fish oil, goose fat , halibut liver oil, pork hand oil, menhaden oil, ox foot oil, oil, salmon oil, sardine oil, shark oil, wool oil and tallow oil. In some embodiments, examples of petrochemical-derived oils for use in the disclosed process include, but are not limited to, mineral oil, silicone oil, petroleum jelly and mixtures of C9-20 alkanes. .
    [0157]
    [0158] In some embodiments, the requirements for a dry extract are a content, preferably, of 35-70% by weight of silymarin, the silymarin part comprising the following fractions of 40-65% by weight: silibinin A and B (diastereomeric mixture, C25H 22O10, MW 482.4); 10-20% by weight of isosilibinin A and B (diastereomeric mixture, C25H22O10, MW 482.4); and 20-45% by weight: ailidanine and silicristin (C25H22O10, MW 482.4).
    [0159]
    [0160] Utilization and pharmaceutical compositions
    [0161]
    [0162] Also disclosed in the present specification is a pharmaceutical formulation comprising an effective amount of the milk thistle fruit extract disclosed in the present specification.
    [0163]
    [0164] In some embodiments, the pharmaceutical formulation comprising the fruit extract of the milk thistle disclosed in the present specification is used for the treatment and prevention of liver and gallbladder dysfunction, in particular, for hepatic damage by toxic (fatty liver, alcohol), hepatosis, such as mushroom poisoning, acute liver failure, liver necrosis, liver necrosis, liver disease, liver cirrhosis, hepatic fibrosis, hepatomegaly, and fatty degeneration of the liver, liver failure, and hepatitis, particularly hepatitis C.
    [0165]
    [0166] In some embodiments, the pharmaceutical formulation comprising extract of the milk thistle fruit disclosed herein is used for the treatment and prevention of liver diseases, such as fascioliasis, hepatitis, nonalcoholic steatohepatitis (NASH) with fibrosis or without fibrosis, hepatic steatosis, fatty liver disease (FLD), nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease, Allagille syndrome, biliary atresia, galactosemia, gallstones, hemochromatosis, liver cancer, deficiency of lysosomal acid lipase (LALD), porphyria, acetaminophen hepatotoxicity, Reye's syndrome, sarcoidosis, tyrosinemia, Wilson's disease, Gilbert's syndrome, cirrhosis and primary sclerosing cholangitis.
    [0167]
    [0168] The extracts of the milk thistle fruit that are disclosed in the present specification can be provided in the form of pharmaceutical preparations in dosage units. In some embodiments, the preparation is present in the form of individual parts, for example pills, dragees, capsules, pills, suppositories, and ampoules, the content of active substance of which, optionally, corresponds to a fraction or multiples of a single dose . The dosage units may contain, for example, 1, 2, 3 or 4 individual doses. An individual dose preferably contains the amount of active substance that is dispensed in an administration and which usually corresponds to a full daily dose or a half, a third or a quarter of a daily dose.
    [0169]
    [0170] The pharmaceutically suitable, non-toxic, inert carrier substances are understood to mean solid, semi-solid, or liquid diluents, fillers and formulation adjuvants of all types.
    [0171]
    [0172] Preferred pharmaceutical formulations are pills, dragees, capsules, pills, granules, suppositories, solutions, syrups, suspensions, and emulsions. The pills, dragees, capsules, pills, and granules may comprise the active substance or substances in addition to usual carrier substances, such as a) fillers and extenders, for example starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders, carboxymethylcellulose, alginates, gelatins, and polyvinylpyrrolidone, c) humectants, for example glycerin, d) disintegrants, for example agar-agar, carbonate calcium, and sodium carbonate, e) solubility retardants, for example paraffin, f) absorption accelerators, for example quaternary ammonium compounds, g) wetting agents, for example cetyl alcohol and glycerin mono stearate, h) adsorbents, for example kaolin and bentonite, and i) lubricants, for example talc, calcium and magnesium stearate, and solid polyethylene glycols, or mixtures of the substances that have been discussed in a) to i).
    [0173]
    [0174] The pills, dragees, capsules, pills, and granules can be provided with customary coatings and coatings that optionally contain opacifying agents, and can also have a composition, such that they release the active substance or substances only in the intestinal tract or , preferably, in a specific part thereof, optionally in a delayed manner, in which the polymeric substances and waxes, for example, can be used as encapsulation compounds.
    [0175]
    [0176] The active substance or substances may also be present in microencapsulated form, optionally with one or more of the carrier substances referred to above.
    [0177]
    [0178] In addition to the active substance or substances, the suppositories may contain customary water-soluble or water-insoluble carrier substances, for example, polyethylene glycols, fats, for example coconut butter and higher esters (for example, C14 alcohol with C16 fatty acid), or mixtures of these substances.
    [0179]
    [0180] In addition to the active substance or substances, the solutions and emulsions may contain carrier substances, such as solvents, solubilizers, and emulsifiers, for example water, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate. , propylene glycol, 1,3-butylene glycol, dimethylformamide, oils, in particular cottonseed oil, peanut oil, wheat germ oil, olive oil, castor oil, and sesame oil, glycerin, glycerin formal, alcohol tetrahydrofurfuryl, polyethylene glycols, and esters of sorbitan fatty acids, or mixtures of these substances.
    [0181]
    [0182] In addition to the active substance or substances, suspensions may contain substances customary carriers, such as liquid diluents, for example water, ethyl alcohol, and propylene glycol, suspending agents, for example ethoxylated isostearyl alcohols, polyoxyethylene sorbitan, and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and gum tragacanth, or mixtures of these substances. The formulation forms referred to may also contain colorants, preservatives and fragrance and flavor enhancing additives, for example, peppermint oil and eucalyptus oil, and sweeteners, for example saccharin.
    [0183]
    [0184] A dietary supplement composition comprising the product of any of the processes described therein is disclosed in the present specification. In some embodiments, the dietary supplement composition is a pill, lozenge, capsule, pill, granule, solution, syrup, suspension or emulsion. In some embodiments, the dietary supplement composition is for use in the modification of liver function. In some embodiments, the dietary supplement composition is used for the treatment and prevention of liver diseases, such as fascioliasis, hepatitis, nonalcoholic steatohepatitis (NASH) with fibrosis or without fibrosis, hepatic steatosis, fatty liver disease (FLD), nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease, Allagille syndrome, biliary atresia, galactosemia, gallstones, hemochromatosis, liver cancer, deficiency of lysosomal acid lipase (LALD), porphyria, acetaminophen hepatotoxicity, Reye, sarcoidosis, tyrosinemia, Wilson's disease, Gilbert's syndrome, cirrhosis and primary sclerosing cholangitis.
    [0185]
    [0186] EXAMPLES
    [0187]
    [0188] Example 1
    [0189]
    [0190] The dissolution of isomers of silymarin in milk thistle products was determined using a dissolution apparatus that meets the requirements of the European Pharmacopoeia (Ph. Eur) and the US Pharmacopoeia of the United States. The dissolution apparatus has a blade conformation and the dissolution medium is a buffer solution at pH 7.5 (degassed).
    [0191]
    [0192] Extract 1 was prepared according to the steps of paragraph [0034] above without adding the oil fraction of steps (a) and (b) in step (e). Extract 2 was prepared according to all steps (a) through (f) in paragraph [0034].
    [0193]
    [0194]
    [0195] Example 2
    [0196]
    [0197] Analysis by gas chromatography of extract 2 which results in a fatty acid content of 3.8% by weight. Analysis by gas chromatography of extract 1 resulted in a fatty acid content of 1.0% by weight.
    [0198]
    [0199] Although preferred embodiments of the present invention have been shown and described in the present specification, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes and substitutions will occur that will occur to those skilled in the art, without departing from the invention. It should be understood that various alternatives of the embodiments of the invention that are described herein can be used at the time of practicing the present invention. It is intended that the following claims define the scope of the present invention and thereby encompass the procedures and structures within the scope of these claims and their equivalents.
    [0200]
    [0201] Example 3
    [0202]
    [0203] Clinical trial 1
    [0204]
    [0205] It will be randomized that participants receive silymarin or a vitamin supplement. Participants from a cohort of individuals infected with hepatitis C will be screened and will receive supplements daily for 18 months, with measurements taken every six months. A pill comprising 210 mg of silymarin daily will be taken. The measurements to be evaluated will include: retention in the study, compliance with the study assignment, self-described symptoms, alanine aminotransferase levels, serum collagen markers, abdominal ultrasound, viral load and clearance, and quality of life.
    [0206] Clinical trial 2
    [0207]
    [0208] The study will be a double-blind, placebo-controlled trial. The present inventors will compare a course of 4 weeks of therapy with silymarin pills containing 400 mg of silymarin and a preparation of low dose vitamins (placebo) administered daily and then monitored for a total of 8 weeks to evaluate the response to the treatment. The results of the randomized controlled trial of the present inventors are improvement in symptoms and signs, normalization of liver functions, time in resuming normal activities and sense of well-being.
    [0209]
    [0210] It will be assayed in finished serum to collect anti-HAV IgM, anti-HBc IgM, anti-HB, HB Ag, antiHCV antibody, HCV-RNA, anti-HDV IgM, anti-HEV IgM, CMV and EBV and alanine aminotransferase (ALT) , AST, direct and total bilirubin.
    [0211]
    [0212] Clinical trial 3
    [0213]
    [0214] This study will be an open, randomized study of dose determination. There will be three groups corresponding to three different doses of IdB 1016: 314 mg, 624 mg, and 942 mg tid. Each group will have 15 patients diagnosed with chronic hepatitis C and five patients will be stratified with stage II fibrosis (periportal fibrosis), five patients with stage III fibrosis (bridge fibrosis), and five patients with stage IV fibrosis (compensated cirrhosis). ). The duration of the treatment will be 12 weeks.
    [0215]
    [0216] Patients will be followed up for an additional 4 weeks after completing treatment to evaluate the residual effects of the measured parameters. Patients will have clinical visits on day -21 (screening) day 1 (initiation of treatment), day 29, day 57, day 85 (end of treatment) and day 113 (follow-up after pharmacological rest).
    权利要求:
    Claims (72)
    [1]
    1. Powerful marian thistle extract obtained through the following process:
    (a) provide an oily milk thistle extract obtained by defatting the milk thistle fruit;
    (b) collecting the oily extract from (a) in an organic solvent to form a solution; (c) providing an additional extract of defatted milk thistle fruit, in which the additional extract is obtained by washing the defatted milk thistle fruit with a solvent and then removing said solvent;
    (d) collecting the additional extract from (c) in a solvent to form a solution;
    (e) combining the solution of (b), with the solution of (d) to form a combined solution of extracts, such that the amount of oily extract of (a) in the final product of (f) is 0 , 5-10.0% by weight;
    (f) removing the solvent from the combined extract solution of (e) to obtain a solid and, optionally, pulverizing the solid;
    wherein the product has a silymarin release rate of 90% or higher.
    [2]
    2. Product according to claim 1, wherein the solution of (b) is concentrated and / or filtered.
    [3]
    3. Product according to claim 1 or 2, wherein the solution of (d) is concentrated and / or filtered.
    [4]
    4. Product according to any of claims 1-3, wherein the solution of (e) is concentrated and / or filtered.
    [5]
    5. Product according to any of claims 1-4, wherein the dry extract of (c) and / or (f) is sprayed.
    [6]
    6. Product according to any of claims 1-5, wherein the dry extract of (c) is re solvated in an organic solvent, optionally, concentrated and / or optionally filtered and dried and optionally , it is pulverized before step (d).
    [7]
    7. Product according to any of claims 1-6, in which the oily milk thistle extract of (a) is obtained by cold pressing of the milk thistle fruit.
    [8]
    8. Product according to any of claims 1-6, wherein the thistle extract Oily mariano from (a) is obtained by washing the milk thistle fruit with an organic solvent.
    [9]
    9. Product according to claim 8, wherein the solvent is a hydrocarbon solvent.
    [10]
    10. Product according to any of claims 1-6, in which the oily marian milk thistle extract from (a) is obtained by extraction with gases or supercritical fluids.
    [11]
    11. Product according to claim 10, wherein the extraction is carried out with supercritical carbon dioxide.
    [12]
    12. Product according to any of claims 1-11, wherein the oily milk thistle extract obtained from (a) is 5-35% by weight of the unprocessed milk thistle fruit, wherein the 65-95 % of the remaining weight is the result of defatted milk thistle.
    [13]
    13. Product according to any of claims 1-12, wherein the solvent of (b) is an alcohol.
    [14]
    14. Product according to claim 13, wherein the solvent is ethanol.
    [15]
    15. Product according to any of claims 1-14, wherein the solvent of (c) is ethyl acetate, ethanol, methanol, or acetone.
    [16]
    16. Product according to claim 15, wherein the solvent of (c) is ethyl acetate.
    [17]
    17. Product according to any of claims 1-16, wherein the solvent of claim (d) is an alcohol.
    [18]
    18. Product according to claim 17, wherein the solvent is ethanol.
    [19]
    19. Product according to any of claims 1-18, wherein the amount of oily extract in (e) is 0.5-6.0% by weight.
    [20]
    20. Product according to claim 19, wherein the amount of oily extract in (e) is 1-3% by weight.
    [21]
    21. Product according to any of claims 1-20, wherein the product has a silymarin release rate of 91% or higher.
    [22]
    22. Milk thistle product comprising an extract of milk thistle and an oil.
    [23]
    23. Marian thistle product according to claim 22, in which the milk thistle extract is obtained by washing a defatted milk thistle fruit with a solvent and then removing said solvent afterwards.
    [24]
    24. Milk thistle product, according to claim 22 or 23, in which the defatted milk thistle fruit is obtained by cold pressing, thus extracting a milk thistle oil.
    [25]
    25. Milk thistle product according to any of claims 22-24, wherein the oil is a vegetable oil, an animal oil, a petroleum oil, or any combination thereof.
    [26]
    26. Marian thistle product according to any of claims 22-25, wherein the oil is a vegetable oil, an essential oil, an herbal oil, or any combination thereof.
    [27]
    27. Marian thistle product according to any of claims 22-26, wherein the oil is a milk thistle oil.
    [28]
    28. Milk thistle product according to any of claims 22-27 in which the milk thistle oil is obtained by defatting the fruit of the milk thistle.
    [29]
    29. Milk thistle product according to any of claims 22-28, wherein the defatting process is cold pressing.
    [30]
    30. Milk thistle product according to any of claims 22-29, in which the milk thistle extract is obtained by washing the defatted milk thistle fruit with ethyl acetate, ethanol, or methanol, and then the elimination, later, of said solvent.
    [31]
    31. Milk thistle product according to any of claims 22-30, wherein the product is obtained by the combination of milk thistle oil with the solvated milk thistle extract, and the elimination of all solvents.
    [32]
    32. Pharmaceutical composition comprising a therapeutically effective amount of a product, according to any of claims 1-31.
    [33]
    33. Pharmaceutical composition according to claim 32 and at least one pharmaceutically acceptable carrier.
    [34]
    34. Pharmaceutical composition according to claim 32, wherein the pharmaceutical composition is a pill, a dragee, a capsule, a pill, a granule, a suppository, a solution, a syrup, a suspension or an emulsion.
    [35]
    35. Process for the treatment or prevention of diseases of the liver, stomach or gall bladder in a subject by administration of a product, according to any of claims 1-31.
    [36]
    36. Procedure for the treatment or prevention of a liver disease, according to claim 35, wherein the liver disease is hepatic damage by toxic, hepatosis, acute liver failure, hepatic necrosis, hepatic necrosis, liver cirrhosis, liver fibrosis, hepatomegaly, fatty degeneration of the liver, liver failure and hepatitis.
    [37]
    37. The method according to claim 35, wherein the liver disease is selected from the group comprising fascioliasis, hepatitis, nonalcoholic steatohepatitis (NASH) with fibrosis or without fibrosis, hepatic steatosis, fatty liver disease (FLD), disease of nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease, Allagille syndrome, biliary atresia, galactosemia, gallstones, hemochromatosis, liver cancer, deficiency of lysosomal acid lipase (LALD), porphyria, acetaminophen hepatotoxicity, Reye's syndrome , sarcoidosis, tyrosinemia, Wilson's disease, Gilbert's syndrome, cirrhosis and primary sclerosing cholangitis.
    [38]
    38. The method according to claim 36, wherein the hepatitis is hepatitis C.
    [39]
    39. The method according to claim 37, wherein the liver disease is Non-alcoholic fatty liver disease.
    [40]
    40. Process for the preparation of extract of the milk thistle fruit that has a silymarin release rate of 90% or higher, the procedure comprising:
    (a) provide an oily milk thistle extract obtained by defatting the fruit of milk thistle;
    (b) collecting the oily extract from (a) in an organic solvent to form a solution; (c) providing an additional extract of defatted milk thistle fruit, in which the additional extract is obtained by washing the defatted milk thistle fruit with a solvent and then removing said solvent;
    (d) collecting the additional extract from (c) in a solvent to form a solution;
    (e) combining the solution of (b), with the solution of (d) to form a combined solution of extracts, such that the amount of oily extract of (a) in the final product of (f) is 0 , 5-10.0% by weight;
    (f) removing the solvent from the combined extract solution of (e) to obtain a solid and, optionally, pulverize the solid.
    [41]
    41. The method according to claim 40, wherein the solution of (b) is concentrated and / or filtered.
    [42]
    42. The method according to claim 40 or 41, wherein the solution of (d) is concentrated and / or filtered.
    [43]
    43. The method according to any of claims 40-42, wherein the solution of (e) is concentrated and / or filtered.
    [44]
    44. Process according to any of claims 40-43, wherein the dry extract of (c) and / or (f) is sprayed.
    [45]
    45. The method according to any of claims 40-44, wherein the dry extract of (c) is re solvated in an organic solvent, optionally, concentrated and / or optionally filtered and dried and optionally , it is pulverized before step (d).
    [46]
    46. The method according to any of claims 40-45, wherein the oily marian milk thistle extract from (a) is obtained by cold pressing the fruit of the milk thistle.
    [47]
    47. The method according to any of claims 40-45, wherein the oily marian milk thistle extract from (a) is obtained by washing the milk thistle fruit with an organic solvent.
    [48]
    48. The process according to claim 47, wherein the solvent is a hydrocarbon solvent.
    [49]
    49. The method according to any of claims 40-45, wherein the oily marian milk thistle extract from (a) is obtained by extraction with gases or supercritical fluids or in combination therewith.
    [50]
    50. The method according to claim 49, wherein the extraction is carried out with supercritical carbon dioxide.
    [51]
    51. The method according to any of claims 40-50, wherein the oily milk thistle extract obtained from (a) is 5-35% by weight of the unprocessed milk thistle fruit, wherein the 65-95 % of remaining weight is the result of defatted milk thistle.
    [52]
    52. The method according to any of claims 40-51, wherein the solvent of (b) is an alcohol.
    [53]
    53. The method according to claim 52, wherein the solvent is ethanol.
    [54]
    54. Process according to any of claims 40-53, wherein the solvent of (c) is ethyl acetate, ethanol or methanol.
    [55]
    55. The process according to claim 54, wherein the solvent of (c) is ethyl acetate.
    [56]
    56. The method according to any of claims 40-55, wherein the solvent according to claim (d) is an alcohol.
    [57]
    57. Process according to claim 56, wherein the solvent is ethanol.
    [58]
    58. The method according to any of claims 40-57, wherein the amount of Oily extract in (e) is 0.5-6.0% by weight.
    [59]
    59. The method according to claim 58, wherein the amount of oily extract in (e) is 1-3% by weight.
    [60]
    60. Product according to any of claims 40-59, wherein the product has a silymarin release rate of 91% or higher.
    [61]
    61. Process for the preparation of an enhanced marinated milk thistle extract comprising an extract of milk thistle and an oil, wherein the addition of said oil to said milk thistle extract results in an increase in the release rate of silymarin .
    [62]
    62. The method according to claim 61, wherein the oil is derived from vegetable, animal or petrochemical sources.
    [63]
    63. The method according to claim 61 or 62, wherein the oil is derived from a plant.
    [64]
    64. Process according to any of claims 61-63, wherein the oil is derived from fruits, seeds or vegetables.
    [65]
    65. Process according to any of claims 61-64, wherein the oil is derived from fruits and / or seeds of milk thistle.
    [66]
    66. The method according to any of claims 61-65, wherein the rate of release is improved by 1.0% or more.
    [67]
    67. The method according to any of claims 61-66, wherein the rate of release is improved by 5.0% or more.
    [68]
    68. The method according to any of claims 61-67, wherein the rate of release is improved by 10.0% or more.
    [69]
    69. The method according to any of claims 61-68, wherein the rate of release is improved by 20.0% or more.
    [70]
    70. Dietary supplement composition comprising the product, according to any of claims 1-31.
    [71]
    71. Dietary supplement composition according to claim 70, wherein the dietary supplement composition is a pill, lozenge, capsule, pill, granule, solution, syrup, suspension, or emulsion.
    [72]
    72. Composition of dietary supplement, according to claim 70 or 71, for use in the modification of liver function.
    类似技术:
    公开号 | 公开日 | 专利标题
    AU2016204819A1|2017-07-20|Multi-supplement compositions
    KR20180125612A|2018-11-23|Avocado flesh and/or skin extract rich in polyphenols and cosmetic, dermatological and nutraceutical compositions comprising same
    Nair et al.2014|Promising anti-diabetes mellitus activity in rats of β-amyrin palmitate isolated from Hemidesmus indicus roots
    Shushunov et al.2009|Determination of acute toxicity of the aqueous extract of Potentilla erecta | rhizomes in rats and mice
    JP5275251B2|2013-08-28|Composition comprising an extract of a combined herb for preventing and treating liver disease
    KR101523586B1|2015-05-29|Pharmaceutical composition for preventing or treating prostatic hyperplasia and preparation method thereof
    KR20100117074A|2010-11-02|Composition containing capsicum for treating a skin disorder
    AU2013320237A1|2015-04-09|Novel extracts of Cynara scolymus, Coffea spp. and Olea europaea for the treatment of metabolic syndrome
    JP2010513473A5|2011-01-27|
    ES2706008A1|2019-03-27|IMPROVED SOLUBILITY OF MARIANO CARDO EXTRACT |
    JP2022505979A|2022-01-14|A composition for alleviating skin irritation and protecting skin derived from environmental pollutants, which contains nutmeg extract or mace lignan as an active ingredient.
    JP2010280734A|2010-12-16|Anti-obesity agent having lipase inhibitory activity and antioxidant property
    TW200526193A|2005-08-16|Anti-aging composition
    JP6124710B2|2017-05-10|Preparation with saw palmetto extract
    Negm2019|Effect of Soybean, Virgin Coconut and Moringa oleifera Seed Oils on the Propylthiouracil Induced Hypothyroidism in Rats
    WO2010002406A1|2010-01-07|Compositions comprising rhodiola rosea and methods of use thereof
    JP2011012021A|2011-01-20|Blood sugar-controlling composition
    US20100003351A1|2010-01-07|Compositions comprising rhodiola rosea and methods of use thereof
    JP6061754B2|2017-01-18|Preparation with saw palmetto extract
    Rojas-Bedolla et al.2018|Chemical characterization, pharmacological effects, and toxicity of an ethanol extract of Celtis pallida Torr.| aerial parts
    JP6938121B2|2021-09-22|Soft-shelled turtle ginseng combination formulation
    JP2004292368A|2004-10-21|Anti-obesity agent
    Bharskar2020|Review on phytochemistry and pharmacological aspects of Pedalium murex Linn
    Sudha et al.2016|Natural Medicines Enhancing Neurite Growth in Central Nervous System Disorders: A Review
    Lim2013|Lycium barbarum
    同族专利:
    公开号 | 公开日
    US20190091273A1|2019-03-28|
    KR20200057006A|2020-05-25|
    ES2706008B2|2021-06-16|
    RU2020111823A|2021-10-22|
    CA3075936A1|2019-03-28|
    AU2018336098A8|2020-04-30|
    EP3684390A1|2020-07-29|
    AU2018336098A1|2020-04-23|
    JP2020535132A|2020-12-03|
    ES2706008B8|2021-07-12|
    WO2019058179A1|2019-03-28|
    RU2020111823A3|2021-10-22|
    CN111107862A|2020-05-05|
    BR112020004948A2|2020-09-15|
    PH12020550098A1|2020-09-14|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    WO2001001961A1|1999-07-05|2001-01-11|Hanmy Pharm. Co., Ltd.|Oral micro-emulsion composition of silybin|
    US20110027396A1|2007-12-23|2011-02-03|Euromed Sa|Novel milk thistle extract, method for the production, and use|
    US20120108825A1|2009-05-14|2012-05-03|Euromed S.A.|Amorphous silibinin for the treatment of viral hepatitis|
    WO2013124700A2|2012-02-24|2013-08-29|University Of Debrecen|Composition containing hepatoprotective sylibum marianum seed oil and procedure for preparation of seed oil|
    FR2181188A5|1972-04-20|1973-11-30|Dott Inverni Della Beffa|Polyhydroxyphenylchromones - by solvent extn of non-defatted fruit of Silybum marianum|
    DE2914330C2|1979-04-09|1987-10-29|Dr. Madaus & Co, 5000 Koeln, De|
    DE3225688A1|1982-07-09|1984-01-12|Suschnik Matthias Dr|Process for the isolation of silymarin from Silybum marianum|CN111714454A|2020-07-22|2020-09-29|宿迁医美科技有限公司|Perilla seed oil and silybum marianum seed oil compounded fat emulsion and preparation method thereof|
    法律状态:
    2019-03-27| BA2A| Patent application published|Ref document number: 2706008 Country of ref document: ES Kind code of ref document: A1 Effective date: 20190327 |
    2021-06-16| FG2A| Definitive protection|Ref document number: 2706008 Country of ref document: ES Kind code of ref document: B2 Effective date: 20210616 |
    优先权:
    申请号 | 申请日 | 专利标题
    US201762562293P| true| 2017-09-22|2017-09-22|
    [返回顶部]